Gayatri Bioorganics Limited has announced its unaudited financial results for the third quarter of fiscal year 2026, ended December 31, 2025. The company reported a net loss of ₹21.71 lakhs for the quarter, representing a significant increase from the ₹16.06 lakhs loss recorded in the corresponding quarter of the previous year.

Financial Performance Overview

The company's quarterly performance showed deterioration across key metrics. With no revenue from operations reported during the quarter, the entire loss stemmed from operational expenses totaling ₹21.71 lakhs.

Expense Breakdown

The company's expenses for Q3 FY26 were distributed across three main categories. Employee benefits expenses stood at ₹2.55 lakhs, up from ₹2.14 lakhs in the previous year quarter. Finance costs increased to ₹9.44 lakhs from ₹7.53 lakhs, while other expenses rose to ₹9.72 lakhs compared to ₹6.39 lakhs in Q3 FY25.

Nine-Month Performance

For the nine-month period from April 1, 2025, to December 31, 2025, Gayatri Bioorganics reported a cumulative net loss of ₹69.13 lakhs, substantially higher than the ₹55.19 lakhs loss in the corresponding period of the previous year.

Regulatory Compliance and Publication

Pursuant to SEBI Regulation 47, Gayatri BioOrganics Limited published its unaudited financial results in newspapers on February 11, 2026. The company published the results in Financial Express (English newspaper) and Nava Telangana (Telugu newspaper), providing investors with QR code access to complete financial results on the company's webpage.

Corporate Governance and Board Approval

The Board of Directors, in their meeting held on February 10, 2026, at 11:30 AM at the company's registered office, considered and approved the unaudited financial results. The meeting concluded at 12:25 PM. The results were reviewed by the Audit Committee before being taken on record by the Board. The company has filed the outcome of the board meeting with BSE Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Financial Highlights

The company maintained its paid-up equity share capital at ₹7,878.81 lakhs throughout the reporting period. Basic and diluted earnings per share stood at ₹(0.03) for the quarter, compared to ₹(0.02) in the corresponding previous quarter. No exceptional items were reported during the quarter, and the company operates as a single segment business.

The financial statements have been prepared on a going concern basis, supported by a comfort letter from the company's promoters regarding future business continuity. The results were prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. MGR & CO, Chartered Accountants, conducted the limited review of the unaudited financial results.

Gayatri Bioorganics Limited (ISIN: INE052E01015) has announced a significant change in its key managerial personnel. The company's Board of Directors has approved the appointment of Ms. Huda Khan as the new Company Secretary and Compliance Officer, effective September 15, 2025.

Board Meeting Details

The decision was made during a board meeting held on September 15, 2025, at the company's registered office. The meeting commenced at 15:10 and concluded at 15:40, as per the official communication to the BSE Limited.

About Ms. Huda Khan

Ms. Khan brings a wealth of experience to her new role at Gayatri BioOrganics:

• Qualifications: She is a qualified Company Secretary.
• Experience: Ms. Khan has over 8 years of experience in secretarial work.
• Appointment Terms: Her appointment follows the existing norms for Key Managerial Personnel (KMPs) of the company.
• Shareholding: Ms. Khan does not hold any shares in the company.
• Relationships: She has no relationships with other directors of Gayatri BioOrganics Limited.

Regulatory Compliance

The appointment of Ms. Khan is in line with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has duly informed the BSE Limited about this appointment, adhering to the necessary disclosure requirements.

Company Leadership

The official communication to the BSE was signed by Mr. Sreedhara Reddy Kanaparthi, the Whole-time Director of Gayatri BioOrganics Limited, who holds the Director Identification Number (DIN) 09608890.

This appointment marks a new chapter for Gayatri BioOrganics as they strengthen their management team with experienced professionals. Ms. Khan's extensive background in secretarial work is expected to contribute significantly to the company's compliance and governance efforts.